Publication

Breast Cancer Research 

 

  1. Daphne SC Lee, Sook-Yee Yoon, Lai Meng Looi, Peter Kang, In Nee Kang, Kavitta Sivanandan, Hany Ariffin, Meow Keong Thong, Kin Fah Chin, Nur Aishah Mohd Taib, Cheng Har Yip and Soo Hwang Teo. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Research (2012) 14:R66.
  2. Suhwan Chang, Rui-Hong Wang, Keiko Akagi, Kyung-Ae Kim, Betty K. Martin, Luca Cavallone, kConFab, Diana C. Haines, Mark Basik, Phuong Mai, Elizabeth Poggi, Claudine Isaacs, Lai M. Looi and Kein S. Mun, Mark H. Greene, Stephen W. Byers, Soo H. Teo, Chu-Xia Deng and Shyam K. Sharan.  Tumor Suppressor BRCA1 epigenetically controls oncogenic miRNA-155. Nature Medicine (2011) in press
  3. Yoon SY, Thong MK, Taib NA, Yip CH, Teo SH. Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study. Fam Cancer. (2011) Feb 12. [Epub ahead of print
  4. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Laura Putignano A, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramón Y Cajal T, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gómez Garcia EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Gareth Evans D, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, John Kennedy M, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frénay M; CEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Tea MK, Pfeiler G, Catharina Dressler A, Hansen TV, Jønson L, Ejlertsen B, Bjork Barkardottir R, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Ewart Toland A, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB; kConFab investigators, Neuhausen SL, Chun Ding Y, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; on behalf of CIMBA.  Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) in press
  5. A Mitra, EK. Bancroft, Y Barbachano, EC. Page, CS Foster, C Jameson, G. Mitchell, GJ Lindeman, A. Stapleton, G. Suthers, DG Evans, D Cruger, I Blanco, C Mercer, J Kirk, L Maehle, S Hodgson, L Walker, L Izatt, F Douglas, K Tucker, H Dorkins, V Clowes, A Male, A Donaldson, C Brewer, R Doherty, B Bulman, PJ Osther, M Salinas, D Eccles, K Axcrona, I Jobson, B Newcombe, C Cybulski, WS Rubinstein, S Buys, S Townshend, E Friedman, S Domchek, T Ramony Cajal, A. Spigelman, SH Teo, N Nicolai, N Aaronson, A Ardern-Jones, C Bangma, D Dearnaley, J Eyfjord, A Falconer, H Grönberg, F. Hamdy, O. Johannsson, V. Khoo, Z. Kote-Jarai, H. Lilja, J. Lubinski,  J. Melia, C. Moynihan, S. Peock, G. Rennert, F. Schröder, P. Sibley, M. Suri, P. Wilson, Y. J. Bignon, S. Strom, M. Tischkowitz, A. Liljegren, D. Ilencikova, A. Abele, K. Kyriacou, C. van Asperen, L. Kiemeney, Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. The IMPACT Study Collaborators, D. F. Easton and R Eeles BJU Int. (2011) 107(1):28-39
  6. Kang P, S Mariapun, Phuah SY, LS Lim, JJ Liu, Yoon SY, Thong MK, NA Mohd Taib, Yip CH and Teo SH. Large genomic rearrangements in BRCA1 and BRCA2 in Malaysian breast cancer patients. Breast Cancer Res Treat (2010) 124(2):579.
  7. Yip CH, Taib NA, Choo WY, Rampal S, Thong MK, Teo SH. Clinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country. World J Surg. (2009) 33: 2077 – 81.
  8. Tan GH, Taib NA, Choo WY, Teo SH, Yip CH. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev. (2009) 10(3):395-8.
  9. E Thirthagiri, Cheong LS, CH Yip and SH Teo. CHEK2 1100delC does not contribute significantly to breast cancer risk in Malaysia’s multi-ethnic population. Familial Cancer (2009) 8(4): 355-8.
  10. E Thirthagiri, SY Lee, P Kang, D Lee, GT Toh, SA Selamat, SY Yoon, NATaib, MK Thong, CH Yip, and SH Teo. Evaluation of BRCA1 and BRCA2 mutations and risk prediction models in a typical Asian country (Malaysia) with relatively low incidence of breast cancer. Breast Cancer Research (2008) 10 R59.
  11. GT Toh, P Kang, SS Lee, DS Lee, SY Lee, SA Selamat, NA Taib, SY Yoon, CH Yip and SH Teo. BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PlosOne (2008)3(4) e2024.

 

Oral Cancer research

 

  1. Daphne SC Lee, Sook-Yee Yoon, Lai Meng Looi, Peter Kang, In Nee Kang, Kavitta Sivanandan, Hany Ariffin, Meow Keong Thong, Kin Fah Chin, Nur Aishah Mohd Taib, Cheng Har Yip and Soo Hwang Teo. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Research (2012) 14:R66.
  2. Suhwan Chang, Rui-Hong Wang, Keiko Akagi, Kyung-Ae Kim, Betty K. Martin, Luca Cavallone, kConFab, Diana C. Haines, Mark Basik, Phuong Mai, Elizabeth Poggi, Claudine Isaacs, Lai M. Looi and Kein S. Mun, Mark H. Greene, Stephen W. Byers, Soo H. Teo, Chu-Xia Deng and Shyam K. Sharan.  Tumor Suppressor BRCA1 epigenetically controls oncogenic miRNA-155. Nature Medicine (2011) in press
  3. Yoon SY, Thong MK, Taib NA, Yip CH, Teo SH. Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study. Fam Cancer. (2011) Feb 12. [Epub ahead of print
  4. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Laura Putignano A, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramón Y Cajal T, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gómez Garcia EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Gareth Evans D, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, John Kennedy M, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frénay M; CEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Tea MK, Pfeiler G, Catharina Dressler A, Hansen TV, Jønson L, Ejlertsen B, Bjork Barkardottir R, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Ewart Toland A, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB; kConFab investigators, Neuhausen SL, Chun Ding Y, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; on behalf of CIMBA.  Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) in press
  5. A Mitra, EK. Bancroft, Y Barbachano, EC. Page, CS Foster, C Jameson, G. Mitchell, GJ Lindeman, A. Stapleton, G. Suthers, DG Evans, D Cruger, I Blanco, C Mercer, J Kirk, L Maehle, S Hodgson, L Walker, L Izatt, F Douglas, K Tucker, H Dorkins, V Clowes, A Male, A Donaldson, C Brewer, R Doherty, B Bulman, PJ Osther, M Salinas, D Eccles, K Axcrona, I Jobson, B Newcombe, C Cybulski, WS Rubinstein, S Buys, S Townshend, E Friedman, S Domchek, T Ramony Cajal, A. Spigelman, SH Teo, N Nicolai, N Aaronson, A Ardern-Jones, C Bangma, D Dearnaley, J Eyfjord, A Falconer, H Grönberg, F. Hamdy, O. Johannsson, V. Khoo, Z. Kote-Jarai, H. Lilja, J. Lubinski,  J. Melia, C. Moynihan, S. Peock, G. Rennert, F. Schröder, P. Sibley, M. Suri, P. Wilson, Y. J. Bignon, S. Strom, M. Tischkowitz, A. Liljegren, D. Ilencikova, A. Abele, K. Kyriacou, C. van Asperen, L. Kiemeney, Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. The IMPACT Study Collaborators, D. F. Easton and R Eeles BJU Int. (2011) 107(1):28-39
  6. Kang P, S Mariapun, Phuah SY, LS Lim, JJ Liu, Yoon SY, Thong MK, NA Mohd Taib, Yip CH and Teo SH. Large genomic rearrangements in BRCA1 and BRCA2 in Malaysian breast cancer patients. Breast Cancer Res Treat (2010) 124(2):579.
  7. Yip CH, Taib NA, Choo WY, Rampal S, Thong MK, Teo SH. Clinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country. World J Surg. (2009) 33: 2077 – 81.
  8. Tan GH, Taib NA, Choo WY, Teo SH, Yip CH. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev. (2009) 10(3):395-8.
  9. E Thirthagiri, Cheong LS, CH Yip and SH Teo. CHEK2 1100delC does not contribute significantly to breast cancer risk in Malaysia’s multi-ethnic population. Familial Cancer (2009) 8(4): 355-8.
  10. E Thirthagiri, SY Lee, P Kang, D Lee, GT Toh, SA Selamat, SY Yoon, NATaib, MK Thong, CH Yip, and SH Teo. Evaluation of BRCA1 and BRCA2 mutations and risk prediction models in a typical Asian country (Malaysia) with relatively low incidence of breast cancer. Breast Cancer Research (2008) 10 R59.
  11. GT Toh, P Kang, SS Lee, DS Lee, SY Lee, SA Selamat, NA Taib, SY Yoon, CH Yip and SH Teo. BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PlosOne (2008)3(4) e2024.

 

NPC Cancer research

 

  1. M. Ahmad, C. Dawson, S.P. Gan, R. Pathmanathan, V.K. Kumar, P.V.H. Lim, G. Selvaratnam, L.M. Looi, A.S.B. Khoo, P.G. Murray, C.C. Ng, S.H. Teo and L.F. Yap. An oncogenic role for Four-Jointed Box 1 (FJX1) in EBV-associated nasopharyngeal carcinoma. (Submitted)
  2. S.J. Chai, K.C. Pua, A. Saleh, Y.Y. Yap, P.V.H. Lim, S.K. Subramaniam, C.L. Lum, G. Krishnan, W.R. Wan Mahiyuddin, the Malaysian NPC Study Group, S.H. Teo, A.S.B. Khoo and L.F. Yap. Clinical significance of plasma Epstein-Barr virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma. J Clin Virol (2012), http://dx.doi.org/10.1016/j.jcv.2012.05.017
  3. P.Y Yew, T. Mushiroda, K. Kiyotani, G.K. Govindasamy, L.F. Yap, S.H. Teo, P.V. Lim, S. Govindaraju, K. Ratnavelu, C.K. Sam, Y.Y. Yap, A.S Khoo, K.C Pua, Y. Nakamura, The Malaysian NPC Study Group, C.C. Ng. Identification of a functional variant in SPLUNC1 associated with nasopharyngeal carcinoma susceptibility among Malaysian Chinese. Molecular Carcinogenesis (2011) doi: 10.1002/mc.21857 [Epub ahead of print].
  4. L.F. Yap, A. Munirah, M.M. Zabidi, S.J. Chai, T.L. Chu, S.K. Tan, W. Wei, P.G. Murray, S.H. Teo, A.S.B. Khoo. Wnt5A acts as an oncogene in EBV-associated nasopharyngeal carcinoma. European Journal of Cancer Supplements (2010) 8(5): 195.
  5. L.F. Yap, V. Jenei, C.M. Robinson, K. Moutasim, T.M. Benn, S.P. Threadgold, V. Lopes, W. Wei, G.J. Thomas, I.C. Paterson. Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation. Oncogene (2009) 28(27):2524-34.
  6. S. Bose*, L.F. Yap*, M. Fung, J. Starzcynski, A. Saleh, S. Morgan, C.W. Dawson, M.B. Chukwuma, E. Maina, M. Buettner, W. Wei, J. Arrand, P.V.H. Lim, L.S. Young, S.H. Teo, T. Stankovic, C.B.J. Woodman and P.G. Murray. The ATM tumor suppressor gene is downregulated in EBV-associated nasopharyngeal carcinoma. J Pathol (2009) 217: 345-352 (*equal contribution).
  7. C.C. Ng, P.Y. Yew, S.M. Puah, G. Krishnan, L.F. Yap, S.H. Teo, P.V. Lim, S. Govindaraju, K. Ratnavelu, C.K. Sam, A. Takahashi, M. Kubo, N. Kamatani, Y. Nakamura, T. Mushiroda. A genome-wide association study identifies ITGA9 conferring risk of nasopharyngeal carcinoma. J Hum Genet (2009) 54(7):392-7.
  8. K.R.N. Baumforth, A. Birgersdotter, G.M. Reynolds, W. Wei, G. Kapatai, J.R. Flavell, E. Kalk, K. Piper, S. Lee, L. Machado, K. Hadley, A. Sundblad, J. Sjoberg, M. Bjorkholm, A.A. Porwit, L.F. Yap, S.H. Teo, R.G. Grundy, L.S. Young, I. Ernberg, C.B.J. Woodman and P.G. Murray. Expression of the Epstein-Bar virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin’s lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol (2008) 173(1):195-204.
  9. K.C. Pua, A.S.B Khoo, Y.Y. Yap, S.K. Subramaniam, C.A Ong, G. Gopala Krishnan, H. Shahid, The Malaysian NPC Study Group. Nasopharyngeal carcinoma database. Malaysian Nasopharyngeal Study Group. Med J Malaysia. 63 (2008) (Suppl C): 59-62.(S.H. Teo and L.F. Yap are members of The Malaysian Nasopharyngeal Study Group).
Patent:
1.      A method for the assessment of cancer in a biological sample obtained from a subject. Patent number: WO/2010/147452. Filed on 10th June 2010.

 

Drug Discovery

 

  1.  YV Tang, SM Phang, WL Chu, ASH Ho, SH Teo, HB Lee. Cyclic Tetrapyrrolic Photosensitisers from Cladophora patentiramea (Cladophoraceae, Chlorophyta) and Turbinaria conoides (Sargassaceae, Phaeophyta) for Photodynamic Therapy. Journal of Applied Phycology 2011, accepted
  2. N Frimayanti, ML Yam, HB Lee, R Othman, SM Zain and NA Rahman. Validation of quantitative structure-activity relationship (QSAR) model for photosensitizer activity prediction. Int. J. Mol. Sci. 2011, 12, 8626-8644 (DOI:10.3390/ijms12128626)
  3. ST Von, HL Seng, HB Lee, SW Ng, Y Kitamura, M Chikira, CH Ng. DNA molecular recognition and cellular selectivity of anticancer metal (II) complexes of EDDA and phenanthroline: multiple targets. Journal of Biological Inorganic Chemistry 2011, 17(1):57-69 (DOI:10.1007/s00775-011-0829-0)
  4. PJ Tan, CY Ong, A Danial, HM Yusof, BK Neoh, HB Lee. Cyclic Tetrapyrrolic Photosensitisers from the leaves of Phaeanthus ophthalmicus.Chemistry Central Journal 2011, 20:5(1):32-39 (DOI:10.1186/1752-153X-5-32)
  5. SH Lim, HB Lee, ASH Ho. A New Naturally-derived Photosensitiser and Its Phototoxicity on Head and Neck Cancer Cells. Photochemistry and Photobiology 2011, 87(5):1152-1158 (DOI:10.1111/j.1751-1097.2011.00939.x)
  6. FA Kamarulzaman, K Shaari, ASH Ho, NH Lajis, SH Teo, HB Lee. Derivatives of Pheophorbide-a and –from Photo-cytotoxic Piper penangenseextract. Chemistry & Biodiversity 20118(3):494-502 (DOI: 10.1002/cbdv.201000341)
  7. PJ Tan, DR Appleton, MR Mustafa, HB Lee. Rapid Identification of Photosensitisers for Photodynamic Therapy using On-Line Hyphenated LC-PDA-MS coupled with photo-cytotoxicity assay. Phytochemical Analysis 2011, 23(1): 52–59 (DOI:10.1002/pca.1324)
  8. Lim SH, C Thivierge, P Nowak-Sliwinska, J Han, H van den Bergh, G Wagnières ,K Burgess, HB Lee. In vitro and In vivo photo-cytotoxicity of BODIPY derivatives for photodynamic therapy. Journal of Medicinal Chemsitry 2010, 53(7):2865-7474 (DOI:10.1021/jm901823u)
  9. SH Lim, P Nowak-Sliwinska, FA Kamarulzaman, H van den Bergh,  G Wagnières, HB Lee. The Neovessel Occlusion Efficacy of 15-Hydroxypurpurin-7-Lactone Dimethyl Ester Induced with Photodynamic Therapy. Photochemistry and Photobiology 2010, 86:397-402 (DOI: record/162653)
  10. HB Lee. Incidence and Risk Factors for Cancer in Malaysia. Berita IKM Chemistry in Malaysia (2009) Issue no 96 p14.
  11. SH Lim, L Wu, K Burgess, HB Lee. New Cytotoxic Rosamine Derivatives Selectively Accumulate in Mitochondria of Cancer Cells. Anticancer Drugs 2009, 20(6): 461-8 (doi: 10.1097/CAD.0b013e32832b7bee)
  12. CY Ong, SK Ling, R Mat Ali, CF Chee, Z Abu Samah, ASH Ho, SH Teo, HB Lee J. Systematic analysis of in vitro photo-cytotoxic activity in extracts from terrestrial plants in Peninsula Malaysia for photodynamic therapy. Photochem. Photobiol. B 2009, 96(3):216-22 (doi.org/10.1016/j.jphotobiol.2009.06.009)
  13. N Kamal, V Sabaratnam, N Abdullah, ASH Ho, SH Teo and HB Lee. Light-activated Cytotoxic Compounds from Malaysian Microorganisms for Photodynamic Therapy (PDT) of Cancer. Antonie van Leeuwenhoek 2009 95(2):179-188 (DOI:10.1007/s10482-008-9301-8)
  14. CY Ong, SE How, SH Puah, SH Mahassan, K Suppayah, HH Teoh, NK Wong, SH Teo, ASH Ho, HB Lee and CC Ho. Screening of Red Extracts from Actinomycetes and Fungi for Photodynamic Therapy. Beyond Medicinal Plants University Publication Centre (UPENA) UiTM (2008) 27-34.
  15. SK Ling, CF Chee, HB Lee, ASH Ho, MA Rasadah, AS Zainon, MGH Khoo and A Norhayati. Screening of Selected Species of Malaysian Medicinal Plants for Photodynamic Properties. Highlights of FRIM’s Non-IRPA Projects (2006) 53-7.
  16. HB Lee, ASH Ho, SH Teo. p53 status does not affect photodynamic cell killing induced by Hypericin. Cancer Chemother Pharmacol. 2006, 58:91-98 (DOI:10.1007/s00280-005-0131-3)
  17. CF Chee, HB Lee, HC Ong, ASH Ho. Photo-cytotoxic pheophorbide-related compounds from Aglaonema simplex. Chemistry & Biodiversity2005, 2:1648-1655 (DOI:10.1002/cbdv.200590134)